Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Latest filing alerts

Every SEC filing alert our engine sent, newest first: 8-K material events, deals, capital raises, leadership changes, results and insider buying and selling.

8:01 AM ET 10-Q
Financial Results Nuvera Communications, Inc. NUVR

Nuvera Communications Q3 2026 Results: Net Loss of $176K, Loss Narrows

Nuvera Communications reported total operating revenues of $17.4 million for the third quarter of 2026, a slight decrease from $18.0 million in the prior year, primarily due to lower A-CAM/FUSF and video service revenues. Despite the revenue dip, operating income improved to $2.66 million as the company reduced operating expenses, though it ultimately recorded a net loss of $176,261 for the quarter due to high interest expenses.

Key figure
Net loss $176K
8:01 AM ET 10-Q
Financial Results TerraVolt Holdings, Inc. GEDC

TerraVolt Holdings Q3 2026 Results: Net Loss of $1.66M, Loss Widens

TerraVolt Holdings, Inc. reported a net loss of $3.9 million for the nine months ended September 30, 2026, compared to a $5.7 million loss in the prior year period. The company is currently pre-revenue and focused on financing and constructing proposed data center operations, with total assets increasing to $13.55 million primarily due to new restricted cash and other assets.

Key figure
Net loss $1.66M
8:01 AM ET 8-K
Investor Presentation Ani Pharmaceuticals Inc ANIP

Ani Pharmaceuticals Investor Presentation

ANI Pharmaceuticals published an updated corporate investor presentation for November 2026 to its website. The presentation outlines the company's strategic transformation into a leading rare disease company, including its proposed acquisition of Egetis Therapeutics and growth strategies for products like Cortrophin Gel and ILUVIEN.

8:01 AM ET 8-K
Financial Results Jasper Therapeutics, Inc. JSPR

Jasper Therapeutics Financial Results

Jasper Therapeutics reported financial results for the third quarter ended September 30, 2026, and provided a corporate update following its acquisition of Kira Pharmaceuticals. The company highlighted progress in its Phase 2 renal basket study for vensobafusp alfa (KP104), including completed enrollment in the IgA nephropathy cohort and the dosing of the first patient with IC-MPGN.

“We have made progress advancing our development programs in recent months following our acquisition of Kira Pharmaceuticals, highlighted by the recent completion of enrollment in the first cohort of our Phase 2 renal basket study evaluating vensobafusp alfa (KP104) in patients with IgA nephropathy (IgAN).”

Jeet Mahal, President and Chief Executive Officer of Jasper

“We believe that the bifunctional ability of vensobafusp alfa to inhibit both the alternative and terminal complement pathways may provide the potential for differentiated onset and efficacy in complement driven diseases, and we look forward to presenting interim data from the IgAN cohort in the fourth quarter of 2026 and additional updates from our pipeline programs in 2027.”

Jeet Mahal, President and Chief Executive Officer of Jasper
8:01 AM ET 8-K
Business Update Super League Enterprise, Inc. SLE

Super League Enterprise Business Update

Super League Enterprise, Inc. announced the purchase of eight Bitcoin at an average price of approximately $68,948.90 per coin. The acquisition is part of the company's strategy to explore Bitcoin as a treasury reserve asset alongside its existing cash and cash equivalents.

8:01 AM ET 8-K
Financial Results Venu Holding Corp VENU

Venu Holding Financial Results

Venu Holding Corp reported its Q3 2026 financial results, highlighting a 59% increase in total assets to $587.6 million since year-end 2025. The company is transitioning from a construction phase to an operational phase with the upcoming opening of the Regent Bank Amphitheater on New Year's Eve and the Sunset Amphitheater McKinney in Q1 2027.

Term
Q3 2026

“Next quarter, VENU moves from building to operating. With two venues coming online, we expect to see a meaningful step up in ticketing, food and beverage, and sponsorship revenue in fiscal 2027. Content drives all of it, and we already have more than 110 holds on the calendar across our portfolio.”

J.W. Roth, Founder, Chairman, and Chief Executive Officer

“What you see in our results today is the cost of bringing more than $600 million in assets online by mid-2027, and we continue to expect to be in a position to provide financial guidance in the middle of next year.”

J.W. Roth, Founder, Chairman, and Chief Executive Officer
8:01 AM ET 8-K
Financial Results Outdoor Holding Co POWW

Outdoor Holding Financial Results

Outdoor Holding Company reported its fiscal second quarter 2027 results, featuring a 14.6% revenue increase to $13.7 million and net income growth to $2.3 million. The company outperformed the broader firearms market with a 10.3% increase in Gross Merchandise Value (GMV) and a 25 basis point increase in take rate to 6.59%.

Term
Q2 2027
8:01 AM ET 8-K
Bankruptcy & Restructuring Childrens Place, Inc. PLCE

Childrens Place Bankruptcy & Restructuring

The Children’s Place, Inc. and certain subsidiaries filed for Chapter 11 bankruptcy protection in the U.S. Bankruptcy Court for the District of New Jersey. The company secured $282 million in debtor-in-possession (DIP) financing, consisting of a $166 million asset-based revolving facility and a $116 million term loan facility to fund operations and case administration. The financing includes the refinancing of prepetition debt and is subject to court-approved budget and variance compliance.

Counterparty
Wells Fargo Bank, National Association
Term
through March 2027
8:01 AM ET 8-K
Capital Raise Strategy Inc MSTR

Strategy Capital Raise of $245M

Strategy Inc reported that it sold 2,087,040 shares of Class A Common Stock (MSTR) under its at-the-market offering program between November 9 and November 15, 2026, generating net proceeds of $244.7 million. The company utilized $33.4 million of these proceeds to purchase 485 additional bitcoins and $206.3 million to fund repurchases of its Variable Rate Series A Perpetual Stretch Preferred Stock (STRC).

Value
$245M
8:01 AM ET 8-K
Leadership Change Relmada Therapeutics, Inc. RLMD

Relmada Therapeutics Leadership Change

Relmada Therapeutics appointed Jørn Skibsted Jakobsen, MD, PhD, as Chief Development Officer, Urology & Uro-Oncology. Dr. Jakobsen previously led the global clinical development of ADSTILADRIN at Ferring Pharmaceuticals and will now lead Relmada's planned Phase 3 SPECTRUM registrational program for NDV-01 in bladder cancer.

8:01 AM ET 8-K
Clinical Trial Data Pasithea Therapeutics Corp. KTTA

Pasithea Therapeutics Clinical Trial Data

Pasithea Therapeutics announced positive initial Phase 1/1b clinical data for PAS-004 in patients with neurofibromatosis type 1 (NF1), showing that all 15 evaluable participants experienced reductions in cutaneous neurofibroma (cNF) surface area. The company also reported that the FDA has cleared its Investigational New Drug (IND) application to proceed with a Phase 2 trial of PAS-004 in adults with NF1-associated cNF.

8:01 AM ET Form 4
Insider Buying Hubspot Inc HUBS

Hubspot CEO Brian Halligan Buys $5M of Stock

Brian Halligan, CEO, bought 22,985 shares of Hubspot Inc at $217.44 a share, worth $5M in total on Nov 13, 2026. Shares held after the trade: 82,485 (+38.6%).

Value
$5M
Shares
22,985
Price
$217.44
Role
CEO
Holding change
+38.6%
Trade date
Nov 13, 2026
8:01 AM ET Form 4
Insider Buying Vivani Medical, Inc. VANI

Vivani Medical Insider Gregg Williams Buys $47.8K of Stock

Gregg Williams bought 48,100 shares of Vivani Medical, Inc. at $0.993 a share, worth $47.8K in total on Nov 13, 2026. Shares held after the trade: 36,960,836 (+0.1%).

Value
$47.8K
Shares
48,100
Price
$0.9930
Holding change
+0.1%
Trade date
Nov 13, 2026
8:01 AM ET 8-K
Loan & Debt Optimum Communications, Inc. OPTU

Optimum Communications $102M Debt Financing with ad hoc group of debtholders

Optimum Communications' subsidiary CSC Holdings elected to skip $102.5 million in interest payments due on three series of senior notes, entering a 30-day grace period to avoid default. The company is utilizing the grace period to maximize flexibility during ongoing negotiations with an ad hoc group of debtholders regarding a potential restructuring of its $22 billion debt load. Operations continue as normal, and the non-payment does not currently trigger cross-defaults under other indebtedness.

Value
$102M
Counterparty
ad hoc group of debtholders
Term
30-day grace period
8:00 AM ET 8-K
Business Update Strive, Inc. ASST

Strive Business Update

Strive, Inc. provided a weekly update on its treasury holdings, disclosing the purchase of 251 bitcoin for approximately $17.5 million between November 7 and November 13, 2026. As of November 13, the company held 43,404 bitcoin and $465.3 million in cash and cash equivalents. The company also reported raising $10.02 million in gross proceeds through the sale of 104,478 shares of its 15.00% Series A Perpetual SATS Preferred Stock under its at-the-market offering program.

7:59 AM ET Form 4
Insider Selling Radcom Ltd RDCM

Radcom Director Sami Totah Sells $66K of Stock

Sami Totah, Director, sold 6,000 shares of Radcom Ltd at $11.00 a share, worth $66K in total on Nov 12, 2026. Shares held after the trade: 24,175 (-19.9%).

Value
$66K
Shares
6,000
Price
$11.00
Role
Director
Holding change
-19.9%
Trade date
Nov 12, 2026
7:59 AM ET 8-K
Leadership Change Walmart Inc. WMT

Walmart Leadership Change

Walmart Inc. has appointed Joseph E. Creed, the Chairman and CEO of Caterpillar Inc., to its Board of Directors, effective November 13, 2026. Mr. Creed will serve on the Audit and Strategic Planning and Finance Committees and will receive a prorated portion of the standard non-management director compensation, which includes a $230,000 annual stock award and a $115,000 annual retainer.

Counterparty
Joseph E. Creed
7:58 AM ET Form 4
Insider Selling Radcom Ltd RDCM

Radcom CTO Ram Amit Sells $33K of Stock

Ram Amit, CTO, sold 3,000 shares of Radcom Ltd at $10.99 a share, worth $33K in total on Nov 13, 2026. Shares held after the trade: 75,813 (-3.8%).

Value
$33K
Shares
3,000
Price
$10.99
Role
CTO
Holding change
-3.8%
Trade date
Nov 13, 2026
7:56 AM ET 10-Q
Financial Results LanzaTech Global, Inc. LNZA

LanzaTech Global Q3 2026 Results: Net Loss of $178M

LanzaTech Global, Inc. reported total revenues of $30.5 million for the nine months ended September 30, 2026, compared to $27.8 million in the prior year period. The company significantly reduced its research and development expenses from $41.7 million to $10.8 million year-over-year, contributing to a narrowed accumulated deficit. However, the filing includes a cautionary note regarding the company's ability to continue as a going concern and its need for additional financing.

Key figure
Net loss $178M
7:56 AM ET 8-K
Financial Results Galectin Therapeutics Inc GALT

Galectin Therapeutics Financial Results

Galectin Therapeutics reported financial results for the quarter ended September 30, 2026, and provided a business update on its Phase 3 clinical trial protocol for belapectin in MASH cirrhosis. The company reached alignment with the FDA on the Phase 3 trial design and presented positive new analyses from its NAVIGATE trial at the AASLD Annual Meeting.

Term
3 months

“New analyses were presented at AASLD, marking the fourth consecutive major liver conference where Galectin data was included in an oral presentation. We were extremely pleased by the positive feedback received on the oral presentation as well as the two poster presentations and are excited that our data was included in the AASLD conference highlights and the portal hypertension debrief.”

Joel Lewis, Chief Executive Officer and President of Galectin Therapeutics

“As previously disclosed, we submitted our registrational Phase 3 protocol to FDA in the third quarter after reaching alignment on primary elements of the planned Phase 3 trial design. Additional information is expected to be presented at the Annual Stockholders’ Meeting on December 3, 2026.”

Joel Lewis, Chief Executive Officer and President of Galectin Therapeutics
7:54 AM ET 8-K
M&A Deal IX Acquisition Corp. IXAQF

IX Acquisition M&A Deal Update

IX Acquisition Corp. provided a status update regarding its pending business combination involving Parent and Merger Sub. The filing includes forward-looking statements concerning the anticipated initial enterprise value, post-closing equity value, and the expected timing for the consummation of the transaction.

7:53 AM ET 8-K
M&A Deal Ameris Bancorp ABCB

Ameris Bancorp M&A Deal with Bank of Central Florida Holding Company

Ameris Bancorp (ABCB) has entered into a definitive agreement to acquire Bank of Central Florida Holding Company (BOCF) in an all-stock merger transaction. BOCF shareholders will receive 0.6279 shares of Ameris common stock for each share held, representing an implied value of $51.80 per share. The deal expands Ameris's presence in the Lakeland and Tampa markets and is expected to close in the first quarter of 2027.

Counterparty
Bank of Central Florida Holding Company
7:53 AM ET 8-K
Financial Results LanzaTech Global, Inc. LNZA

LanzaTech Global Financial Results

LanzaTech Global reported Q3 2026 revenue of $9.5 million and a net loss of $178.0 million, which was primarily driven by a $166.4 million non-cash unrealized fair value loss on its investment in SGLT. The company highlighted significant cost reductions, with operating expenses down 35% year-over-year, and achieved the world's first ISCC EU certification for recycled carbon fuels from steel mill waste gases.

Term
Q3 2026

“Our third quarter results show continued improvement in our financial and operating performance, building on the progress we have made throughout 2026. The actions we took to reshape LanzaTech are now showing up in our results quarter after quarter; we have held quarterly operating expenses steady for multiple quarters, which tells us the lower cost base we built is durable and sustainable. Our cost structure is now reset for where we are headed operationally and strategically, and LanzaTech now has a much improved position upon which to advance its platform toward commercialization and long-term profitability.”

Dr. Jennifer Holmgren, CEO of LanzaTech

“We are building a business that can monetize waste carbon across multiple end markets rather than depend on a single route to market. This quarter, Hebei Shoulang, a commercial facility using LanzaTech technology, achieved the world’s first ISCC EU Recycled Carbon Fuel certification for ethanol made from steel mill waste gases. This creates a near-term pathway into European road and marine fuel markets, and we have begun commercial discussions with major energy and chemicals companies to convert certification into revenue.”

Dr. Jennifer Holmgren, CEO of LanzaTech
7:53 AM ET 8-K
M&A Deal Surgery Partners, Inc. SGRY

Surgery Partners M&A Deal with Bon Secours Mercy Health, Inc.

Surgery Partners announced a consent solicitation for its $1.225 billion 7.250% Senior Notes due 2032 to amend the indenture in connection with its pending merger with Spyglass Topco, LLC and Bon Secours Mercy Health. The amendments seek to designate the acquirers as 'Permitted Holders' to prevent the merger from triggering a 'Change of Control' repurchase obligation under the debt agreement.

Counterparty
Bon Secours Mercy Health, Inc.
7:51 AM ET 10-Q
Financial Results Galectin Therapeutics Inc GALT

Galectin Therapeutics Q3 2026 Results: Net Loss of $3.53M, Loss Narrows

Galectin Therapeutics reported a net loss of $17.7 million for the nine months ended September 30, 2026, an improvement from the $25.3 million loss in the prior year period. A significant balance sheet event occurred with the conversion of $105.2 million in debt into common stock, substantially reducing total liabilities and increasing the common shares outstanding to over 100 million.

Key figure
Net loss $3.53M
7:51 AM ET 10-K
Financial Results Tyson Foods, Inc. TSN

Tyson Foods FY 2026 Results: Net Income $453M

Tyson Foods reported 2026 sales of $56.4 billion, a 3.6% increase driven by higher average sales prices and an additional fiscal week. Despite sales growth, net income attributable to Tyson decreased slightly to $453 million, impacted by significant restructuring charges, legal contingency accruals, and continued operating losses in the Beef segment.

Key figure
Net income $453M
7:47 AM ET 8-K
Leadership Change Montauk Renewables, Inc. MNTK

Montauk Renewables Leadership Change

Kevin Van Asdalan informed Montauk Renewables of his intention to resign as Chief Financial Officer, effective December 9, 2026. The company stated the departure is not due to any conflict or disagreement and expects to identify an interim CFO during the transition period.

7:46 AM ET 8-K
Financial Results Montauk Renewables, Inc. MNTK

Montauk Renewables Financial Results

Montauk Renewables reported Q3 2026 revenues of $50.2 million, a 10.9% increase year-over-year, though net income fell 58.9% to $2.1 million. The company announced it has executed a non-binding term sheet to amend its credit facility to borrow additional debt and address liquidity concerns, avoiding a previously anticipated going concern qualification. Additionally, the company plans to invest $15.0 million in enhancements at its Turkey, North Carolina facility to address feedstock moisture and syngas temperature issues limiting commercial production.

Term
Q3 2026
7:45 AM ET 8-K
Financial Results Creative Realities, Inc. CREX

Creative Realities Financial Results

Creative Realities reported Q3 2026 revenue of $26.2 million, a significant increase from $10.5 million in the prior-year period, driven by the acquisition of Cineplex Digital Media and new contract wins. The company reported Adjusted EBITDA of $2.7 million and annualized recurring revenue (ARR) of $21.7 million. Management expects full-year 2026 revenue to exceed $100 million, supported by retail media deployments and stadium installations.

Term
Q3 2026

“We continue to set new records this year in terms of growth acceleration, business wins, and EBITDA expansion. We anticipate revenue exceeding $100 million in fiscal 2026, as the fourth quarter is expected to benefit from seasonal factors related to our retail media contracts as well as from the positive impact of recent awards and new customer installations.”

Rick Mills, Chief Executive Officer

“We focused on the balance sheet this quarter, using existing cash to pay down debt, provide increased financial flexibility, and reduce ongoing interest expense. Our talented staff and leadership successfully executed an operating strategy that is producing significant growth as we become a more nimble organization intent on achieving improved bottom line results and cash generation.”

Rick Mills, Chief Executive Officer
7:45 AM ET 8-K
Clinical Trial Data Cerenome, Inc. CNSY

Cerenome Clinical Trial Data

Cerenome reported interim data from its Phase 1 ReSPECT-LM study evaluating repeat dosing of REYOBIQ in patients with leptomeningeal metastases. The data showed no dose-limiting toxicities in the first 10 patients and indicated consistent radiation delivery across repeat administrations, with early disease control signals showing no progression in evaluable patients at the six-month landmark.

Counterparty
Society for Neuro-Oncology

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.